Author

M. Lockley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Assay:bulk RNA-seq· 3 Approach:statistical model· 3 Research Focus:clustering· 2 Approach:experimental assay· 2 Assay:whole-genome sequencing· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

E. Maniati· 2 shared F. Markowetz· 2 shared F. Nicolini· 2 shared G. Macintyre· 2 shared H. Hockings· 2 shared I. A. McNeish· 2 shared T. Goranova· 2 shared W. Huang· 2 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Maniati

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Adaptive therapy achieves long-term control of chemotherapy resistance in high grade ovarian cancer

H. Hockings, E. Lakatos, W. Huang, M. Mossner, M. A. Khan, S. Metcalf, F. Nicolini, K. Smith, A.-M. Baker, T. Graham, M. Lockley

This study demonstrates that adaptive therapy reduces chemotherapy resistance in ovarian cancer by exploiting fitness costs of resistant cells, extending survival in mice and correlating with disease burden in patients.

bioRxiv · Jul 21, 2023 · PreprintCancer Biology

Extracellular matrix educates a tumor macrophage phenotype found in ovarian cancer metastasis

E. H. Puttock, E. J. Tyler, M. Manni, E. Maniati, C. Butterworth, E. Peerani, P. Hirani, V. Gauthier, Y. Liu, G. Maniscalco, V. Rajeeve, P. Cutillas, C. Trevisan, M. Pozzobon, M. Lockley, , O. M. T. Pearce

The paper shows that the tumor extracellular matrix educates macrophages to adopt a phenotype seen in ovarian cancer metastasis, affecting T cell function and immune regulation.

bioRxiv · Aug 11, 2022 · PreprintCancer Biology

The genomic landscape of early stage ovarian high grade serous carcinoma

Z. Cheng, H. Mirza, D. P. Ennis, P. Smith, L. Morrill, C. Sokota, G. Giannone, T. Goranova, T. Bradley, A. Piskorz, M. Lockley, The BriTROC Investigators, B. Kaur, N. Singh, L. Tookman, , I. McNeish

This study compares genomic features of early and late stage high grade serous ovarian carcinoma, finding no unique mutations or focal copy number alterations but noting differences in ploidy and copy number signatures.

bioRxiv · May 5, 2021Cancer Biology

Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancer

J. I. Hoare, H. Hockings, J. Saxena, V. L. Silva, E. Maniati, H. B. Mirza, W. Huang, G. E. Wood, F. Nicolini, T. A. Graham, I. A. McNeish, M. Lockley

This study investigates platinum resistance in high grade serous ovarian cancer by analyzing transcriptomic features and evolutionary trajectories in resistant models.

bioRxiv · Jul 23, 2020 · PreprintCancer Biology

Copy-number signatures and mutational processes in ovarian carcinoma

G. Macintyre, T. Goranova, D. De Silva, D. Ennis, A. M. Piskorz, M. Eldridge, D. Sie, L.-A. Lewsley, A. Hanif, C. Wilson, S. Dowson, R. M. Glasspool, M. Lockley, E. Brockbank, A. Montes, , J. D. Brenton

This study identifies copy-number signatures in ovarian cancer and links them to mutational processes, showing that most cases involve multiple processes, suggesting therapeutic challenges.

bioRxiv · Sep 4, 2017Cancer Biology